Form 4: Rhythm Pharmaceuticals Executive Pamela Cramer Reports Stock Transactions

Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover withholding taxes.

Summary

• On July 26, 2024, Pamela Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, vested 3,125 shares of common stock from restricted stock units.
• Following the vesting, Ms. Cramer sold 1,395 shares on July 29, 2024, at a price of $49.06 per share.
• The sale was executed under a pre-existing Rule 10b5-1 plan to cover withholding taxes related to the vesting of the restricted stock units.
• After these transactions, Ms. Cramer directly owns 31,735 shares of Rhythm Pharmaceuticals common stock and 3,125 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment with company performance.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning executive incentives with long-term shareholder value.
• Rule 10b5-1 plans are commonly used by corporate insiders to schedule stock sales in advance, avoiding accusations of trading on non-public information.
• The sale of shares to cover withholding taxes is a typical practice among executives receiving equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
• The sale of shares to cover withholding taxes is a standard practice and is unlikely to significantly affect employee morale.

Key Dates